<!DOCTYPE html>
<html lang="en" data-theme="light">
<head><script src="/livereload.js?mindelay=10&amp;v=2&amp;port=1315&amp;path=livereload" data-no-instant defer></script>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Cingulate Inc.&#39;s CTx-1301 Poised to Transform ADHD Treatment Landscape - Building Texas Show News</title>
    
    
    <meta name="description" content="Cingulate Inc. advances CTx-1301 for ADHD, targeting a $22B market with a once-daily treatment. Stonegate initiates coverage, highlighting potential.">
    <meta name="keywords" content="news, breaking news, current events, analysis, journalism">
    <meta name="author" content="Building Texas Show">
    
    
    <meta property="og:title" content="Cingulate Inc.&#39;s CTx-1301 Poised to Transform ADHD Treatment Landscape - Building Texas Show News">
    <meta property="og:description" content="Cingulate Inc. advances CTx-1301 for ADHD, targeting a $22B market with a once-daily treatment. Stonegate initiates coverage, highlighting potential.">
    <meta property="og:type" content="article">
    <meta property="og:url" content="http://localhost:1315/posts/2025-06-18-cingulate-incs-ctx-1301-poised-to-transform-adhd-treatment-landscape/">
    
    <meta property="og:image" content="https://cdn.newsramp.app/reportable/newsimage/c3885a8d9ef373d4dfce66fe01baf167.png">
    
    
    
    <meta name="twitter:card" content="summary_large_image">
    <meta name="twitter:title" content="Cingulate Inc.&#39;s CTx-1301 Poised to Transform ADHD Treatment Landscape - Building Texas Show News">
    <meta name="twitter:description" content="Cingulate Inc. advances CTx-1301 for ADHD, targeting a $22B market with a once-daily treatment. Stonegate initiates coverage, highlighting potential.">
    
    
    <link rel="canonical" href="http://localhost:1315/posts/2025-06-18-cingulate-incs-ctx-1301-poised-to-transform-adhd-treatment-landscape/">
    
    
    <link href="https://cdn.jsdelivr.net/npm/daisyui@4.12.10/dist/full.min.css" rel="stylesheet" type="text/css" />
    <script src="https://cdn.tailwindcss.com"></script>
    
    
    <style>
         
        @import url('https://fonts.googleapis.com/css2?family=Inter:wght@300;400;500;600;700&display=swap');
        
         
        :root {
          --primary: #0f766e;  
          --primary-content: #ffffff;
          --secondary: #64748b;
          --accent: #dc2626;  
          --neutral: #0f766e;  
          --base-100: #ffffff;
          --base-200: #f8fafc;
          --base-300: #e2e8f0;
          --base-content: #1f2937;
          --teal-600: #0d9488;
          --teal-700: #0f766e;
          --teal-800: #115e59;
        }

         
        [data-theme="light"] {
          --primary: #0f766e;
          --primary-content: #ffffff;
          --secondary: #64748b;
          --accent: #dc2626;
          --neutral: #0f766e;
          --base-100: #ffffff;
          --base-200: #f8fafc;
          --base-300: #e2e8f0;
          --base-content: #1f2937;
          background-color: #ffffff;
          color: #1f2937;
        }

         
        html, body {
          font-family: 'Inter', -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, sans-serif;
          background-color: inherit;
          color: inherit;
          line-height: 1.6;
        }

         
        main {
          background-color: #a5f3fc;
          color: #1f2937;
          min-height: calc(100vh - 200px);
        }

         
        .content-card {
          background: rgba(255, 255, 255, 0.95);
          color: #1f2937;
          border-radius: 8px;
          box-shadow: 0 4px 6px -1px rgba(0, 0, 0, 0.1);
        }

         
        h1, h2, h3, h4, h5, h6 {
          font-weight: 600;
          line-height: 1.3;
        }

         
        .btn-primary {
          background-color: #0f766e;
          border-color: #0f766e;
          color: white;
        }

        .btn-primary:hover {
          background-color: #0d9488;
          border-color: #0d9488;
        }

         
        a {
          color: #0f766e;
          text-decoration: none;
        }

        a:hover {
          color: #0d9488;
        }

         
        .nav-hover:hover {
          background-color: var(--primary) !important;
          color: var(--primary-content) !important;
        }

        .dropdown-content {
          background-color: var(--base-100) !important;
          border: 1px solid var(--base-300) !important;
        }

        .dropdown-item:hover {
          background-color: var(--primary) !important;
          color: var(--primary-content) !important;
        }

        .group:hover .group-hover\:block {
          display: block !important;
        }
    </style>
    
</head>
<body class="min-h-screen bg-base-100">
    
<div class="bg-white border-b border-gray-200">
  <div class="container mx-auto px-4 py-4">
    <div class="flex items-center justify-between">
      
      <a href="/" class="flex items-center">
        <img
          src="https://newswriter.ai/logo.svg"
          alt="Newswriter.ai"
          class="h-8 w-auto"
        />
        <span class="text-sm text-gray-500 ml-3"
          >Let AI Write Your Press Release</span
        >
      </a>

      
      <div class="relative">
        <div class="dropdown dropdown-end">
          <div tabindex="0" role="button" class="btn btn-primary">
            Write My Press Release
            <svg
              class="w-4 h-4 ml-1"
              fill="none"
              stroke="currentColor"
              viewBox="0 0 24 24"
            >
              <path
                stroke-linecap="round"
                stroke-linejoin="round"
                stroke-width="2"
                d="M19 9l-7 7-7-7"
              ></path>
            </svg>
          </div>
          <ul
            tabindex="0"
            class="dropdown-content menu bg-base-100 rounded-box z-[1] w-52 p-2 shadow"
          >
            <li><a href="#" class="text-sm">Write New Press Release</a></li>
            <li><a href="#" class="text-sm">Improve Existing Release</a></li>
            <li><a href="#" class="text-sm">View Examples</a></li>
            <li><a href="#" class="text-sm">Pricing</a></li>
          </ul>
        </div>
      </div>
    </div>
  </div>
</div>

    
    <main>
        

<div class="container mx-auto px-4 py-8">
  <div class="max-w-4xl mx-auto">
    
    <div class="text-sm mb-6">
      <a href="/" class="text-primary hover:underline">Home</a>
      <span class="text-gray-500 mx-2"> / </span>
      <span class="text-gray-500">Article</span>
    </div>

    
    <div class="mb-8">
      <h1
        class="text-4xl md:text-5xl font-bold text-base-content leading-tight mb-6"
      >
        Cingulate Inc.&#39;s CTx-1301 Poised to Transform ADHD Treatment Landscape
      </h1>

      
      <div class="border-b border-gray-200 pb-6 mb-8">
        <div class="flex items-center text-sm mb-4">
          <span class="text-primary font-semibold"> Building Texas Show News </span>
          <span class="text-gray-400 mx-2"> • </span>
          <span class="text-base-content opacity-70">
            June 18, 2025
          </span>
        </div>

        
        
        <a
          href="https://stonegateinc.reportablenews.com/pr/stonegate-capital-partners-initiates-coverage-on-cingulate-inc-nasdaq-cing"
          target="_blank"
          class="inline-flex items-center text-primary hover:text-primary-focus underline font-medium"
        >
          Read Original Article →
        </a>
        
      </div>
    </div>

    
    
    <div class="mb-8">
      <img
        src="https://cdn.newsramp.app/reportable/newsimage/c3885a8d9ef373d4dfce66fe01baf167.png"
        alt="Cingulate Inc.&#39;s CTx-1301 Poised to Transform ADHD Treatment Landscape"
        class="w-full h-96 object-cover rounded-lg shadow-lg mb-8"
      />
    </div>
    

    
    
    <div class="bg-base-200 p-6 rounded-lg mb-8">
      <h2 class="text-2xl font-bold text-base-content mb-4">Summary</h2>
      <div
        class="text-lg leading-relaxed mb-8 prose prose-lg max-w-none"
        style="color: var(--base-content)"
      >
        <p>Cingulate Inc. (NASDAQ: CING) has caught the attention of investors and the healthcare sector with its innovative approach to ADHD treatment through its lead asset, CTx-1301, leveraging the proprietary Precision Timed Release™ (PTR™) platform. Stonegate Capital Partners has initiated coverage on Cingulate, highlighting the company's progress towards the commercial launch of CTx-1301, a once-daily stimulant therapy designed to offer rapid onset and sustained efficacy throughout the day, addressing the $22B U.S. ADHD market. Recent Phase 3 pediatric study results have shown statistically significant improvements in ADHD symptoms, with CTx-1301 demonstrating a strong safety profile and flexibility in administration with or without food. Cingulate is on track to submit a New Drug Application (NDA) in mid-2025, aiming to redefine ADHD treatment with the first true once-daily stimulant offering full-day efficacy.</p><p>Financially, Cingulate reported a net loss of $3.8M for 1Q25, with cash and cash equivalents standing at $9.5M. The company is exploring strategic financing options to support its NDA filing and pre-launch activities. Stonegate Capital Partners' valuation of Cingulate ranges from $13.96 to $26.96, with a midpoint of $19.09, indicating potential growth for investors. More details on the valuation can be found on the <a href='https://www.stonegateinc.com'>Valuation page</a>.</p>
      </div>
    </div>
    

    
    <div class="mb-12">
      <h2 class="text-2xl font-bold text-base-content mb-6">Full Article</h2>
      <div
        class="prose prose-lg max-w-none leading-relaxed"
        style="color: var(--base-content)"
      >
        <div class="space-y-4">
          <p class='mb-4'><p>The recent initiation of coverage by Stonegate Capital Partners on Cingulate Inc. (NASDAQ: CING) highlights a pivotal moment in the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD). Cingulate's lead asset, CTx-1301, developed using the company's proprietary Precision Timed Release™ (PTR™) platform, promises to deliver a once-daily stimulant therapy with rapid onset and sustained efficacy. This innovation addresses a critical gap in current ADHD treatments, which often necessitate booster doses, thereby complicating patient adherence.</p><p>In May 2025, Cingulate reported encouraging efficacy results from its FDA-required Phase 3 fixed-dose pediatric trial for CTx-1301. The trial showcased statistically significant improvements on the ADHD-RS-5 scale across all dose levels within five weeks, with effect sizes ranging from 0.737 to 1.185. These findings, complemented by positive outcomes from a high-dose food effect study in April, underscore CTx-1301's potential to revolutionize ADHD management by enhancing treatment adherence and offering greater flexibility to patients.</p><p>Cingulate is on track to submit a New Drug Application (NDA) for CTx-1301 in mid-2025, backed by data from nine clinical trials. The company's recent pre-NDA consultation with the FDA and the submission of final Phase 3 safety results in March 2025 are significant milestones toward achieving regulatory approval. With a robust safety profile and no serious treatment-emergent adverse events reported, CTx-1301 stands out as a promising candidate that could redefine standards in ADHD treatment.</p><p>Financially, Cingulate reported $9.5M in cash and cash equivalents as of the first quarter of 2025, alongside a net loss of $3.8M for the same period. The company is actively exploring strategic financing avenues to bolster its NDA submission and pre-launch initiatives, including a $5M unsecured promissory note secured in December 2024. Stonegate Capital Partners has valued Cingulate between $13.96 and $26.96, with a midpoint of $19.09, reflecting the transformative potential of CTx-1301 in the lucrative $22B U.S. ADHD market.</p><p>The development of CTx-1301 represents a significant advancement in ADHD treatment, offering hope for improved patient outcomes and adherence. As Cingulate progresses toward commercialization, the implications for patients, healthcare providers, and the broader ADHD market are profound, signaling a new era in the management of this pervasive condition.</p></p>
        </div>
      </div>
    </div>

    
    
    <div class="bg-base-200 p-4 rounded-lg mb-8 text-sm text-gray-600">
      
      <p>Article ID: 82963</p>
       
      <p>Feed Item ID: 15723</p>
      
    </div>
    

    
    <div class="text-center">
      <a href="/" class="btn btn-outline btn-lg">← Back to Home</a>
    </div>
  </div>
</div>

    </main>
    
    
<footer class="bg-teal-700 text-white">
  <div class="container mx-auto px-4 py-6">
    <div class="flex flex-col md:flex-row justify-between items-center gap-4">
      <div class="flex items-center gap-4">
        <p class="text-sm">
          Newswriter.ai © 2025 All Rights Reserved
        </p>
        <a href="#" class="text-sm hover:text-teal-200 transition-colors"
          >Privacy Policy</a
        >
        <a href="#" class="text-sm hover:text-teal-200 transition-colors"
          >Terms of Service</a
        >
      </div>

      
      <div class="flex items-center">
        <div
          class="bg-white text-black px-3 py-1 rounded flex items-center gap-2"
        >
          <div class="border-2 border-black rounded px-2 py-1">
            <span class="font-bold text-xs">AI<br />TS</span>
          </div>
          <div class="text-xs">
            <div class="font-semibold">Verified Tool on</div>
            <div class="font-bold">AI Tech Suite</div>
          </div>
          <div class="text-lg">✓</div>
        </div>
      </div>
    </div>
  </div>
</footer>

</body>
</html>
